Nurix Therapeutics (NRIX) Income from Continuing Operations (2019 - 2025)
Historic Income from Continuing Operations for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to -$78.2 million.
- Nurix Therapeutics' Income from Continuing Operations fell 3359.92% to -$78.2 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$264.5 million, marking a year-over-year decrease of 3662.16%. This contributed to the annual value of -$264.5 million for FY2025, which is 3662.16% down from last year.
- According to the latest figures from Q4 2025, Nurix Therapeutics' Income from Continuing Operations is -$78.2 million, which was down 3359.92% from -$86.4 million recorded in Q3 2025.
- Over the past 5 years, Nurix Therapeutics' Income from Continuing Operations peaked at -$24.3 million during Q1 2021, and registered a low of -$86.4 million during Q3 2025.
- Its 5-year average for Income from Continuing Operations is -$45.0 million, with a median of -$43.0 million in 2022.
- In the last 5 years, Nurix Therapeutics' Income from Continuing Operations crashed by 44804.75% in 2021 and then surged by 4652.76% in 2023.
- Nurix Therapeutics' Income from Continuing Operations (Quarter) stood at -$37.7 million in 2021, then decreased by 23.95% to -$46.7 million in 2022, then rose by 10.19% to -$42.0 million in 2023, then tumbled by 39.55% to -$58.5 million in 2024, then plummeted by 33.6% to -$78.2 million in 2025.
- Its last three reported values are -$78.2 million in Q4 2025, -$86.4 million for Q3 2025, and -$43.5 million during Q2 2025.